MX2022014420A - Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos. - Google Patents

Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.

Info

Publication number
MX2022014420A
MX2022014420A MX2022014420A MX2022014420A MX2022014420A MX 2022014420 A MX2022014420 A MX 2022014420A MX 2022014420 A MX2022014420 A MX 2022014420A MX 2022014420 A MX2022014420 A MX 2022014420A MX 2022014420 A MX2022014420 A MX 2022014420A
Authority
MX
Mexico
Prior art keywords
cov
generation
antibodies against
neutralizing antibodies
potent neutralizing
Prior art date
Application number
MX2022014420A
Other languages
English (en)
Inventor
Yang Luo
Pengfei Wang
David D Ho
Yaoxing Huang
Lihong Liu
Manoj S Nair
Jian Yu
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2022014420A publication Critical patent/MX2022014420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La materia aquí descrita se refiere a anticuerpos monoclonales y biespecíficos potentes capaces de neutralizar un virus SARS-CoV-2 y métodos para generar los anticuerpos.
MX2022014420A 2020-05-20 2021-05-20 Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos. MX2022014420A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US202163165729P 2021-03-24 2021-03-24
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Publications (1)

Publication Number Publication Date
MX2022014420A true MX2022014420A (es) 2023-03-21

Family

ID=78707603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014420A MX2022014420A (es) 2020-05-20 2021-05-20 Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.

Country Status (12)

Country Link
US (3) US20240002476A1 (es)
EP (1) EP4153625A2 (es)
JP (1) JP2023526469A (es)
KR (1) KR20230024904A (es)
AU (1) AU2021277373A1 (es)
BR (1) BR112022023467A2 (es)
CA (1) CA3184184A1 (es)
CL (1) CL2022003215A1 (es)
CO (1) CO2022018192A2 (es)
IL (1) IL298263A (es)
MX (1) MX2022014420A (es)
WO (4) WO2021236998A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298263A (en) * 2020-05-20 2023-01-01 Univ Columbia Strong neutralizing antibodies against sars-cov-2, their production and uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007103343A (ru) * 2004-06-30 2008-08-10 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК (CA) Вакцинная композиция и способы лечения коронавирусной инфекции
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
MX2009002418A (es) * 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
NZ592054A (en) * 2008-10-13 2013-06-28 Inst Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
US9403904B2 (en) * 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
CA2932405A1 (en) * 2013-12-02 2015-06-11 Aaron Diamond Aids Research Center Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
EP3261665A1 (en) * 2015-02-24 2018-01-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
EP3842072A1 (en) * 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
JP2018535655A (ja) * 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
TW202016151A (zh) * 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MX2021000009A (es) * 2018-07-09 2021-03-09 Five Prime Therapeutics Inc Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
IL298263A (en) * 2020-05-20 2023-01-01 Univ Columbia Strong neutralizing antibodies against sars-cov-2, their production and uses

Also Published As

Publication number Publication date
JP2023526469A (ja) 2023-06-21
US20240002476A1 (en) 2024-01-04
WO2021236998A9 (en) 2022-03-31
IL298263A (en) 2023-01-01
CA3184184A1 (en) 2021-11-25
KR20230024904A (ko) 2023-02-21
CO2022018192A2 (es) 2023-03-17
WO2021236998A2 (en) 2021-11-25
US20230203134A1 (en) 2023-06-29
WO2021236997A3 (en) 2022-09-29
WO2021236996A2 (en) 2021-11-25
WO2021236998A3 (en) 2021-12-16
AU2021277373A1 (en) 2023-01-05
EP4153625A2 (en) 2023-03-29
BR112022023467A2 (pt) 2023-03-28
WO2021236995A2 (en) 2021-11-25
CL2022003215A1 (es) 2023-07-07
WO2021236996A3 (en) 2022-11-17
WO2021236997A2 (en) 2021-11-25
WO2021236995A3 (en) 2022-09-15
US20230203138A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
PH12020500177A1 (en) Bcma monoclonal antibody-drug conjugate
EA201992469A1 (ru) Антигенспецифические иммунные эффекторные клетки
CR20190434A (es) Anticuerpos anti-lag3
PE20141722A1 (es) Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2019004448A (es) Anticuerpos anti-virus respiratorio sincitial y metodos de generacion y uso de estos.
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
MX2020012064A (es) Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
MX2020010227A (es) Construcciones dirigidas a cd22 y usos de las mismas.
MX2022014653A (es) Composiciones de antigeno de coronavirus y sus usos.
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
MX2021012871A (es) Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
MX2022014420A (es) Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MX2022002269A (es) Plantas transformadas y metodos para elaborar y utilizar las mismas.
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
WO2018128457A3 (ko) 극 부호에 기초하여 정보에 채널 코딩을 수행하는 방법
MX2022015403A (es) Carbón activado modificado por deposición de capa atómica y métodos de la misma.
PE20221039A1 (es) METODOS PARA USAR INMUNOCONJUGADOS ANTI-CD79b PARA TRATAR LINFOMA DIFUSO DE LINFOCITOS B GRANDES
AU2018325899A1 (en) Method for producing influenza HA split vaccine
MX2020005005A (es) Métodos para la expansión selectiva de poblaciones de células t gamma delta delta 3 y composiciones de estas.
EA202091834A1 (ru) Непрерывный способ получения тразодона
MX2023005841A (es) Anticuerpos anti-marco y usos de estos.
SG11201906990WA (en) Method for preparing polythiols